PE20211198A1 - Metodos y formulaciones para tratar nauseas y vomitos inducidos por quimioterapia - Google Patents

Metodos y formulaciones para tratar nauseas y vomitos inducidos por quimioterapia

Info

Publication number
PE20211198A1
PE20211198A1 PE2021000497A PE2021000497A PE20211198A1 PE 20211198 A1 PE20211198 A1 PE 20211198A1 PE 2021000497 A PE2021000497 A PE 2021000497A PE 2021000497 A PE2021000497 A PE 2021000497A PE 20211198 A1 PE20211198 A1 PE 20211198A1
Authority
PE
Peru
Prior art keywords
vomiting
formulations
methods
induced nausea
treat chemotherapy
Prior art date
Application number
PE2021000497A
Other languages
English (en)
Inventor
Catherine Jacobson
Original Assignee
Tilray Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tilray Inc filed Critical Tilray Inc
Publication of PE20211198A1 publication Critical patent/PE20211198A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

SE REFIERE A UNA FORMULACION ORAL SOLIDA QUE COMPRENDE CANNABIDIOL Y DELTA-9- TETRAHIDROCANNABINOL, DONDE LA RAZON EN PESO DEL CANNABIDIOL CON RESPECTO AL DELTA-9-TETRAHIDROCANNABINOL ES DE DESDE 2,0:0,5 HASTA 0,5:2,0; DICHA COMPOSICION COMPRENDE ADEMAS UNA LECITINA, UN DERIVADO DE VITAMINA E, ETANOL Y GLICERINA, SIENDO UTIL EN EL TRATAMIENTO DE NAUSEAS Y VOMITOS INDUCIDOS POR QUIMIOTERAPIA.
PE2021000497A 2018-10-10 2019-10-10 Metodos y formulaciones para tratar nauseas y vomitos inducidos por quimioterapia PE20211198A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862743839P 2018-10-10 2018-10-10
PCT/US2019/055662 WO2020077103A1 (en) 2018-10-10 2019-10-10 Methods and formulations for treating chemotherapy-induced nausea and vomiting

Publications (1)

Publication Number Publication Date
PE20211198A1 true PE20211198A1 (es) 2021-07-01

Family

ID=68345091

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000497A PE20211198A1 (es) 2018-10-10 2019-10-10 Metodos y formulaciones para tratar nauseas y vomitos inducidos por quimioterapia

Country Status (12)

Country Link
US (1) US20200113847A1 (es)
EP (1) EP3863614A1 (es)
JP (1) JP2022502471A (es)
KR (1) KR20210116432A (es)
AU (1) AU2019357608A1 (es)
BR (1) BR112021006858A2 (es)
CA (1) CA3115985A1 (es)
CL (1) CL2021000882A1 (es)
CO (1) CO2021005797A2 (es)
MX (1) MX2021004138A (es)
PE (1) PE20211198A1 (es)
WO (1) WO2020077103A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232379A1 (en) * 2019-05-16 2020-11-19 Aegis Therapeutics, Llc Oil-soluble drug containing compositions and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US20040248970A1 (en) * 2003-04-10 2004-12-09 Webster G.R. Barrie CBD-delta8-THC composition
EP1706098A4 (en) * 2003-11-26 2012-08-15 Supernus Pharmaceuticals Inc MICELLAR SYSTEMS SUITABLE FOR THE DELIVERY OF LIPOPHILIC OR HYDROPHOBIC COMPOUNDS
MX2007014188A (es) * 2005-05-13 2008-02-05 Unimed Pharmaceuticals Inc Tratamiento con dronabinol de nauseas y vomitos tardios inducidos por quimioterapia.
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
KR20160094950A (ko) * 2013-10-31 2016-08-10 풀 스펙트럼 래버러토리즈, 리미티드 테르펜 및 칸나비노이드 제제
EP3463304A4 (en) * 2016-05-24 2020-01-08 Bol Pharma Ltd. COMPOSITIONS COMPRISING CANNABIDIOL AND HYALURONIC ACID FOR THE TREATMENT OF INFLAMMATORY JOINT DISEASES
WO2018058235A1 (en) * 2016-09-27 2018-04-05 CannTab Therapeutics Limited Sustained release cannabinoid formulations
WO2018071581A1 (en) * 2016-10-12 2018-04-19 Columbia Care, Llc An oral composition of extracted cannabinoids and methods of use thereof
BR112019013743A2 (pt) * 2017-01-03 2020-01-21 Receptor Holdings Inc compostos medicinais e suplementos nutricionais
WO2018152334A1 (en) * 2017-02-15 2018-08-23 Molecular Infusions, Llc Formulations
US10307392B2 (en) * 2017-10-21 2019-06-04 Alexander Kariman Compound and method for treatment of diseases and disorders
CA3119786A1 (en) * 2017-11-17 2019-05-23 Tilray, Inc. Cannabinoid compositions
EP3755372A1 (en) * 2018-02-23 2020-12-30 Nicola Michael Spirtos Cannabis based therapeutic and method of use
US20210290552A1 (en) * 2018-07-31 2021-09-23 AusCann Group Holdings Ltd Solid self-emulsifying pharmaceutical compositions

Also Published As

Publication number Publication date
US20200113847A1 (en) 2020-04-16
WO2020077103A1 (en) 2020-04-16
KR20210116432A (ko) 2021-09-27
CO2021005797A2 (es) 2021-05-20
CL2021000882A1 (es) 2021-08-27
MX2021004138A (es) 2021-08-05
EP3863614A1 (en) 2021-08-18
CA3115985A1 (en) 2020-04-16
JP2022502471A (ja) 2022-01-11
AU2019357608A1 (en) 2021-05-27
BR112021006858A2 (pt) 2021-07-13

Similar Documents

Publication Publication Date Title
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
CL2019003635A1 (es) Composiciones y tratamientos para el trastorno del sueño.
DOP2019000104A (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer
DOP2021000183A (es) Compuestos tricíclicos condensados útiles como agentes anticancerígenos
DOP2019000280A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
CO2021007993A2 (es) Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina
UY37617A (es) Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
PE20230607A1 (es) Composicion de cannabis
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
PE20191492A1 (es) Composicion farmaceutica que comprende selexipag
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
CL2019001658A1 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
UY37973A (es) Derivados de indol macrocíclicos
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CO2024000890A2 (es) Compuestos de heteroarilo para tratar la enfermedad de huntington
MX2020004232A (es) Composiciones de cannabinoides y sus metodos de uso.
AR120057A1 (es) Composiciones neoantigénicas y usos de estas
PE20211198A1 (es) Metodos y formulaciones para tratar nauseas y vomitos inducidos por quimioterapia
CL2019002632A1 (es) Preparación que contiene al menos un fungicida químico y una preparación que contiene cepas de aureobasidium pullulans .